Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is funded by PER®.

Current and Novel Approaches in DLBCL

Release Date: September 3, 2020
Expiration Date: September 3, 2021

Acknowledgment of Support

This activity is funded by PER®.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


This continuing medical education (CME) activity is designed to inform health care providers involved in the clinical care of patients with diffuse large B cell lymphoma (DLBCL) of changes to the rapidly evolving treatment landscape in the context of emerging therapies for the treatment of DLBCL. The in-depth program will cover recent updates regarding the treatment of DLBCL, key investigational therapies undergoing evaluation in clinical trials, and their incorporation into novel therapeutic approaches for the management of patients with DLBCL.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Explain current therapeutic regimens in newly diagnosed and relapsed/refractory DLBCL
  • Evaluate efficacy and safety profiles of investigational treatment of DLBCL
  • Describe mechanisms of action for novel targets to treat DLBCL

This activity was written by PER® editorial staff under faculty guidance and review. The Q&A portion of the activity was transcribed from a recorded interview with the faculty and edited by faculty and PER® editorial staff for clarity.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Gilles A. Salles, MD, PhD
Gilles A. Salles, MD, PhD
University Professor
Head of Hematology
Claude Bernard University of Lyon
Hospices Civils de Lyon
Lyon, France

Disclosures: Consultant: AbbVie, Amgen, Autolus Therapeutics, Celgene, Gilead Sciences, Epizyme, Janssen Pharmaceutica, Kite Pharma, MorphoSys, Novartis, Roche, Servier Laboratories, Takeda Pharmaceutical Company.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By